Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study
- 507 Downloads
The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations were analyzed retrospectively. We analyzed chemotherapy-naïve NSCLC patients aged 75 years or older who had EGFR mutations (exon 19 deletion mutation or L858R), who were initially treated with gefitinib (250 mg) once daily in Nagano Prefecture. A total of 55 patients (16 men, 39 women) with a median age of 81.1 years (range; 75–94 years) treated between April 2007 and July 2012 were analyzed. The overall response rate and disease control rate were 72.7 % (95 % confidence interval (CI); 59.5–82.9 %) and 92.7 % (95 % CI; 82.0–97.6 %), respectively. Median progression-free survival and overall survival from the start of gefitinib treatment were 13.8 months (95 % CI; 9.9–18.8 months) and 29.1 months (95 % CI; 22.4 months–not reached), respectively. Two-year survival rate was 59.5 % (95 % CI; 41.0–78.0 %). Major grade 3 toxicities were skin rash (1.8 %) and increased levels of aspartate aminotransferase or alanine aminotransferase (7.3 %). First-line treatment with gefitinib for elderly EGFR-mutated NSCLC patients was effective and well tolerated. The results suggest that first-line gefitinib should be considered as a preferable standard treatment in elderly patients with advanced NSCLC harboring EGFR mutations.
KeywordsNon-small-cell lung cancer Elderly patients First-line EGFR mutations Gefitinib
We thank the patients and their families for their support and participation in this study. We also thank Akihiro Tsukadaira in Iida Municipal Hospital, Muneharu Hayasaka in Chushin Matsumoto Hospital, Akio Morokawa in Showa Inan Hospital, and all of the members of Nagano Lung Cancer Research Group for their helpful support.
Conflict of interest
- 12.Inoue A, Kobayashi K, Usui K, et al. North East Japan gefitinib study group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394–400.PubMedCrossRefGoogle Scholar
- 19.Travis WD, Colby TV, Corrin B et al. Histological typing of lung and pleural tumors. World Health Organization international histological classification of tumors. 3rd ed. Berlin: Springer; 1999.Google Scholar
- 20.Travis WD, Brambilla E, Muller-Hermelink HK et al. Pathology and genetics. Tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.Google Scholar
- 22.Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
- 23.Title of subordinate document. In: Common terminology criteria for adverse events (CTCAE) Version 4.0. National Cancer Institute. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 of subordinate document (2012). Accessed 28 Nov 2012.